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The feasibility of a population-based evaluation of screening for prostate cancer in men with a raised familial risk was investigated by
studying reasons for non-participation and uptake rates according to postal recruitment and clinic contact. The levels of prostate-
specific antigen (PSA) and the positive predictive values (PPV) for cancer in men referred with a raised PSA and in those biopsied
were analysed. First-degree male relatives (FDRs) were identified through index cases (ICs): patients living in two regions of England
and diagnosed with prostate cancer at age p65 years from 1998 to 2004. First-degree relatives were eligible if they were aged 45–
69 years, living in the UK and had no prior diagnosis of prostate cancer. Postal recruitment was low (45 of 1687 ICs agreed to their
FDR being contacted: 2.7%) but this was partly due to ICs not having eligible FDRs. A third of ICs in clinic had eligible FDRs and
49% (192 out of 389) agreed to their FDR(s) being contacted. Of 220 eligible FDRs who initially consented, 170 (77.3%) had a new
PSA test taken and 32 (14.5%) provided a previous PSA result. Among the 170 PSA tests, 10% (17) were X4ngml
 1 and 13.5%
(23) tests above the age-related cutoffs. In 21 men referred, five were diagnosed with prostate cancer (PPV 24%; 95% CI 8, 47). To
study further the effects of screening, patients with a raised familial risk should be counselled in clinic about screening of relatives and
data routinely recorded so that the effects of screening on high-risk groups can be studied.
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The effects of screening by serum prostate-specific antigen (PSA)
on prostate cancer mortality are not known. The European
Randomized Study of Screening for Prostate Cancer (ERSPC)
(Roobol and Schroder, 2003) and the Prostate Lung Colorectal and
Ovarian cancer screening trial in the US (Prorok et al, 2000) offer
screening by the PSA test in men aged 50–69 years (with some
variation in age between participating countries). In addition, in
the UK ProtecT treatment trial of early-stage prostate cancer
(Donovan et al, 2002), general practices are randomised to join
either the trial in which cancers are being detected by offering men
a PSA test or a control arm not entering the trial. The earliest that
results on mortality from these studies will be available is 2010
(Roobol and Schroder, 2003). Even if screening reduces mortality,
there remains concern about the overdiagnosis of clinically
nonsignificant cancer and about the uncertain benefits of radical
treatment in all men diagnosed with prostate cancer compared
with active surveillance (Hardie et al, 2005).
The efficiency of screening might be improved by targeting
moderate- to high-risk groups. Genetic risk of prostate cancer
could account for up to 10–15% of cases. The relative risk of
prostate cancer increases with the number of affected first- or
second-degree relatives diagnosed with prostate cancer, from
about two with a single first-degree relative to 8.8 with both a first-
and second-degree relative (Carter et al, 1993; Verhage et al, 2004)
affected. Several studies outside the UK (Bratt et al, 2000; Makinen
et al, 2002; Roumier et al, 2004; Verhage et al, 2004) have
investigated screening in family members with a high risk of
prostate cancer, but the definitions of high risk vary according to
whether only first-degree or other relatives are included.
The study aims to assess the feasibility of a population-based
approach to evaluating the effects of screening for prostate cancer
in first-degree male relatives (FDRs) of patients diagnosed with
prostate cancer at age p65 years in the UK and to study the impact
of PSA testing on referral for biopsy. Feasibility was assessed by
developing different methods of recruitment and studying uptake
rates and reasons for non-participation at several stages during
this process. Referral rates for FDRs with raised PSA levels, and
the positive predictive value (PPV) of the PSA test in FDRs referred
for biopsy with a raised PSA level, were also analysed. The
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sstudy was not designed to investigate the efficacy of screening.
The results of a psychosocial study conducted in conjunction with
the screening study (refer Sweetman et al, 2006) are reported
separately.
MATERIALS AND METHODS
Procedures for consent and screening are summarised in Figure 1.
The Screening Office (SO) at the Institute of Cancer Research
coordinated the recruitment and data collection in both the postal
phase and clinic phase.
Ethical approval
The study was approved by the South London Multi-centre
Research Ethical Committee (MREC January 2000).
Study population
Index cases (ICs) were defined as patients living in the catchment
areas of two cancer registries (London and the central and western
areas of southern England) diagnosed with prostate cancer
between 1 January 1998 and 31 July 2004 and aged p65 years at
diagnosis. All ICs had to be alive and not considered by
their consultant to be seriously ill or in distress. For those ICs in
Index cases (ICs) with
prostate cancer aged  65 yrs
identified in defined areas (TCR, 
SWCIS and BAUS)
NCRN staff at each 
hospital identified list of
Index cases (ICs) and dates due in
clinic. Checked suitability
for contact.
Wrote to consultant for 
signed consent.
Consultant provided covering 
letter to ICs
IC interviewed by NCRN nurse 
in clinic.  Checked eligibility of
FDRs and IC interest in
participating
Wrote to IC’s GP for consent
Invitation sent to ICs
by SO
IC recruitment 
finished July 2004
From March 
2001 to March 
2003
From June 
2002 to July
2004
No 
NFA
Yes Yes
Yes
Yes
No 
NFA
No 
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No 
NFA
POSTAL PHASE CLINIC PHASE
Figure 1 Procedures to recruit FDRs for PSA screening (IC¼index case; FDR¼first-degree male relative; NFA¼no further action).
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sthe postal phase, their general practitioners (GPs) were also
first approached to check on health status. First-degree male
relatives were eligible for the screening study if they were aged 45–
69 years, living in the UK and had no prior diagnosis of prostate
cancer. Prior PSA measurement did not exclude FDRs from the
study.
IC provided signed consent and FDRs contact details
Invitation letter sent to FDRs
FDRs provide signed consent and GP details to
TAPS sample and/or previous test result
GP sent request to take blood samples
FDR proceeded with blood test
Blood samples taken at GP surgery or hospital using the kit supplied by SO
Samples posted to screening office
One sample used to measure PSA in RMH laboratory, other sample
stored in freezer
FDRs and GP notified result
FDRs and GP advised if referral required
No reply
NFA
No reply
NFA
TAPS
sample
Previous sample
No reply
NFA after
follow-up
Yes
Yes
No
Sample
analysed
at the local
laboratory
SO notified of PSA 
result
Yes
Figure 1 (Continued).
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sIn the postal phase, ICs were identified from the Thames Cancer
Registry (TCR), South West Cancer Intelligence Service (SWCIS)
and the British Association of Urological Surgeons (BAUS)
database. In a pilot postal phase in 2001, only FDRs of ICs
identified through the TCR who lived within easy reach of London
were invited to take part. Referrals in the pilot were assigned to
consultant urologists in London and biopsies (only one FDR
referred) were couriered to MCP for pathological diagnosis. This
restriction was removed when recruitment was expanded.
The clinic phase was developed from July 2002. The study was
adopted by the National Cancer Research Network (NCRN) and
expanded to identify ICs from hospital records who were attending
hospitals in five Cancer Research Networks: Peninsula; Avon,
Somerset and Wiltshire; Dorset; South West London; and Central
South Coast. Working mainly in oncology clinics, but also in some
urology clinics, the NCRN nurses and urological specialist research
nurses identified ICs eligible by date of and age at diagnosis. There
was no standardised data source used by the staff to identify ICs;
some had access to computerised patient lists giving date of birth
and type of cancer. Other hospitals relied on checking patient
notes at the beginning of each clinic. The years of diagnosis and
time periods of data collection from each source are summarised
in Table 1.
Consent and information procedures
Signed consent to approach ICs was required from the consultants
and initially from GPs (Figure 1). Delays in replies led to revisions
so that GPs were notified and contacted by phone, but signed
consent was not required. Signed consent was obtained from each
IC and FDR. In the postal phase, MREC did not permit follow-up
letters to IC non-responders or collection of data on reasons for
non-participation. However, in the clinic phase, a standardised
form was used to collect data on eligibility and reasons for non-
participation, so that invitations were only sent to ICs with a
confirmed FDR. Subsequent procedures were identical for all men.
In the final year of recruitment at two hospitals (Royal Marsden
Hospital (RMH) and Salisbury), a postal invitation was used to
contact ICs who could not be seen in clinic before the closure date
for recruitment.
In the clinic phase, the study could be discussed with the
research nurse and consultant, and an information sheet about the
study, which included a contact number for the SO, was given to
each IC if they expressed an interest in receiving the invitation
letter. In both phases, the information sheet was included with the
invitation letters to both the ICs and the FDRs. First-degree male
relatives were encouraged to discuss the study with their GP.
Screening procedure
First-degree male relatives were invited to provide a blood sample
for the measurement of PSA. Those who had been PSA tested/
screened more than 12 months prior to contact were invited to be
re-screened under the study protocol, while those who had their
PSA measured within 12 months prior to the study invitation were
invited to provide the result of their previous test. The SO sent
each GP a venepuncture kit to collect a 7ml serum sample for PSA
testing. The sample was sent by first class post to the SO using
approved packaging and was analysed at the RMH biochemistry
laboratory using the Abbott AxSym analyser. The guidelines were
based on the NHS Prostate Cancer Risk Management Programme
recommendations (http://www.cancerscreening.nhs.uk/) and pub-
lished results (Oesterling et al, 1993): for ages 45–59 years: refer
if X3ngml
 1, repeat test at 6 months if 2–2.9ngml
 1; for ages
60–69 years: refer if X4ngml
 1, repeat test at 6 months if
3–3.9ngml
 1.
Each GP and FDR was notified by letter of their PSA result and
whether there was a recommendation either for a re-test at 6
months or for referral. Screening started on 6th June 2001 and
continued up to 31st March 2005 to reach the target sample size.
Referral and diagnosis
When referral was recommended, the SO advised the GP about
consultant urologists who were members of BAUS at the hospital
routinely used by the GP. The GP made the final decision
about referral after discussion with the FDR. Once referral was
confirmed, the SO sent the consultant a standardised biopsy
protocol and reporting procedure, based on the BAUS proforma. A
minimum of eight biopsy cores (four per side), ultrasound guided,
was recommended to be taken using an 18-gauge needle. Once the
pathological diagnosis was received from the hospital, a patho-
logical review was requested and conducted by MCP.
Questionnaire data
Each FDR completed a self-administered questionnaire asking
about ethnic group, using the 1991 Census categories, household
composition and marital status at the time of signing consent.
After providing the PSA measurement, the men also completed a
questionnaire on the past history of PSA testing.
Statistical analysis
Simple descriptive analyses were conducted using proportions
and percentage distributions. The main outcome measures, uptake
rates and distributions of PSA levels, were analysed by age for
both ICs and FDRs. Confidence intervals for proportions were
calculated using the exact method for binomial distributions. The
PPV of referral was the proportion of men diagnosed with prostate
cancer on biopsy out of all men with a raised PSA who were
recommended by the study protocol and proceeded to be referred.
The PPV of referral in the general population for PSA testing was
assumed to be 20%, and that in men with familial prostate cancer
to be higher at 50%. Thus, 17 FDRs with a positive PSA test were
needed to have 80% power of detecting a statistically significant
difference between these estimates (Po0.05). Assuming a positive
rate of 10%, a sample size of 170 FDRs was needed.
Table 1 Summary of main sources for identification of index cases
Data source Date of diagnosis Location
Thames Cancer Registry 1998–2000 South Thames
North Thames
South West Cancer Intelligence Service 1998–1999 South West Region
British Association of Urological Surgeons 1998–2001 Thames and South West Region
NCRN centres and urology clinics RMH: January 1998–July 2004
Other: January 2000–July 2004
South West London, South West Region
Not in clinics, so posted invitation RMH: January 1998–July 2004
Other: January 2000–July 2004
RMH and Salisbury
NCRN¼National Cancer Research Network; RMH¼Royal Marsden Hospital.
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sRESULTS
The registries and BAUS database identified a total of 1687 ICs;
1140 ICs were contacted in clinic, and 130 ICs at two hospitals, not
seen in clinic, received invitation letters (Table 2).
Measures of feasibility
Uptake rates by method of recruitment In the postal phase, 48%
of consultants (68 out of 143) responded, giving consent for 515
ICs to be sent invitation letters by the SO (Table 2). General
practitioner’s consent was obtained for 340 out of 515 ICs. An
additional 12 ICs on the BAUS register were invited. Out of 352 ICs
who were sent letters, 45 returned signed consent for the FDRs to
be contacted. (Using this method of contact, it is not known what
proportion of ICs actually had an eligible FDR.) Out of 39 FDRs
who consented either to have their PSA measured or to provide a
previous result and were aged 45–69 years at the time of their PSA
test, 30 proceeded to provide a test result. (Of the 1687 ICs, 186
(11%) were contacted during the pilot when only FDRs living
within reach of London took part, and it is not known how many
ICs did not respond because of this exclusion.)
In the clinic phase, 389 of the 1140 ICs (34%) agreed in clinic to
receive further information and an invitation letter, and 192
(16.8%) returned signed consent, leading to 167 (14.6%) FDRs who
consented and were aged 45–69 years at the time of their PSA test
(Table 2). Two FDRs were aged 44 years when they consented, and
requested to have their PSA test taken when they reached 45.
Of the 167 FDRs consenting, 134 proceeded to have their PSA
measured and 24 provided a previous test result. Two hospitals
identified a further 130 ICs who could not be seen, or had been
missed, in clinic before recruitment closed. Their GPs gave
permission for 117 to be contacted by letter, leading to 10 FDRs
having their PSA measured and four providing a previous result
(Table 2).
Most ICs provided details of one FDR (204 out of 257, 77.5%)
and the remaining 53 provided details of two or more FDRs. Most
FDRs were brothers, but two were sons of ICs.
Reasons for non-participation and characteristics of participants
Non-participation recorded in clinic phase: Of the 1140 ICs
identified in clinic, seven were not approached (consultant
decision), 59 refused (some adding that they had not told their
family that they had cancer), 94 only had FDRs living abroad and
591 reported no suitable relative. There were 16 FDRs reported to
have prostate cancer, but these data are likely to be incomplete.
Characteristics of ICs: Age at diagnosis was recorded on the
database by the SO for all but two ICs identified from the cancer
registries. Age at diagnosis was among the entry criteria used by
the hospital staff, but some centres did not send dates of birth or
diagnosis to the SO for local reasons of confidentiality (697). For
2252 ICs (76%) with known date of birth, the proportion below the
age of 60 years was 41% for those identified at the outset and 45%
for those agreeing to receive the invitation letter.
Characteristics of FDRs: A total of 202 FDRs provided a PSA
measurement: 170 FDRs had their PSA test taken for the study and
32 provided a previous measurement. They were aged 45–69 years
at the time that their blood sample was taken. Just over half of the
FDRs (53%) were aged 45–59 years. All of the FDRs giving consent
returned the self-administered questionnaire. Of these, 98% were
white subjects, 2% were Asian or Chinese, and none were African
or African Caribbean. The majority (87%) were married or co-
habiting, with 6% divorced or separated, 6% single or widowed
and 1% not known. Of 202 FDRs, 185 replied to the question about
having had a PSA test before the one recorded in our study: 128
(69%) said that the PSA measurement provided was their first test
and 57 (31%) reported having had a previous test.
Time to recruit In the postal phase, the median time for ICs to
reply was 10 days (range 1–441 days, 75% interquartiles 22 days).
In the clinic phase, the median time for ICs to reply was 16 days
(range 2–232 days, 75% interquartile 36 days). The times between
the date when an IC was sent an invitation letter and the last date
when a result was recorded for an FDR following the PSA test
(ranging from FDR receiving a negative test result to date of
biopsy) were as follows: in the postal phase, medians of 96 and
85 respectively, 75% interquartiles of 133 and 176 respectively,
range 42–606 days; in the clinic phase, medians of 100 and 149
respectively, 75% interquartiles of 148 and 240 respectively, range
29–705 days.
Prostate-specific antigen measurement
Sources Most PSA measurements (164) were taken according to
the study protocol and analysed at RMH. For the six PSA
measurements taken for the study but analysed locally, the types of
Table 2 The number of ICs and FDRs participating at different stages of the study
Postal phase Clinic phase
Stage
TCR and
SWCIS BAUS Clinic contact only
No clinic contact,
letter sent Total
Total number of ICs identified
a 1368 319 1140 130 2957
Consultant reply and consent 515 60 Consultant consent prior to
clinic contact
Consultant consent prior to
clinic contact
GP consent 340 N/A 117
IC with eligible FDRs confirmed N/A 12
b 389 N/A
IC consent returned with eligible FDR(s) 41 4 192 20 257
FDR consented to provide blood sample or
previous test result, restricted to aged 45–69
years at the time of test
36 3 167 14 220
PSA measurement
Study screen
c 24 2 134 10 170
Previous screen 4 — 24 4 32
aAge p65 years at diagnosis living in defined study areas, diagnosed 1998–2004.
bA total of 12 ICs only had their GP informed.
cIncludes PSA measurements from 164 recorded
at central laboratory and six recorded at the local laboratory of FDR. Calculation of age of FDR in analysis: age of FDR at the date of PSA test. IC¼index case; FDR¼first-degree
male relative; TCR¼Thames Cancer Registry; SWCIS¼South West Cancer Intelligence Service; BAUS: British Association of Urological Surgeons; GP¼general practitioner;
PSA¼prostate-specific antigen.
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sassays were recorded. Variation in measurements between these
assays was checked (the National External Quality Assurance
scheme, Peter White, personal communication, 2005). The six
PSA levels recorded at the local laboratories were such that
the decisions whether or not to refer the FDRs would have
been unaffected by variation in measurement between assays.
Therefore, the PSA results (170) were grouped together in the
data analyses.
Prostate-specific antigen levels Of the 170 PSA tests taken for this
study, 17 (10%) were X4ngml
 1 and 23 (13.5%) were above the
age-related cutoffs. Among the 23 men with raised PSA levels
recommended for referral, 14% (12 out of 88) in the age range 45–
59 years had levels X3ngml
 1 and 13% (11 out of 82) in the age
range 60–69 years had levels above X4ngml
 1. Among the 170
men, the PSA levels ranged from 0.17 to 13.47ngml
 1 in 122 men
who reported no previous PSA test (this included 11 with history
not known) and from 0.23 to 6.10ngml
 1 in 48 men with a
previous test.
Of 23 men with raised PSA, 21 agreed to be referred. The PPV of
referral was 24% (95% CI 8, 47) in the 170 men whose PSA was
measured by the study protocol (Table 3). The proportions
referred were 11% (13 out of 122) and 17% (eight out of 48) in
FDRs with no previous PSA test and in FDRs with a previous test,
respectively. There appeared to be a higher PPV of referral in FDRs
reporting no previous test (31%, 95% CI 9, 61) than in men with a
previous test (12.5%, 95% CI 0, 53) but the numbers were small
and the CI wide. Five cancers were diagnosed, all being clinically
organ confined with Gleason grade distribution: one 2þ2, three
3þ3 and one 4þ3.
In the 32 FDRs providing previous measurements, five (16%)
were X4ngml
 1 and eight (25%) were above the age-related
cutoffs. No cancers were diagnosed in these men.
DISCUSSION
The feasibility of studying the impact of screening on men who
have a raised familial risk of prostate cancer will depend in part on
the uptake rate and the workload involved in identifying eligible
families, and in part on the sample size required to test hypotheses
about the effects of screening. In this study, the uptake rates of ICs
and FDRs, the workload associated with recruitment, and the
referral rate and PPV of referral were studied.
The study demonstrated the importance of personal contact in
clinic with prostate cancer patients, firstly to establish eligibility
and secondly to discuss the study. In the clinic phase, 60% of ICs
(685 out of 1140) reported no suitable relatives or relatives living
abroad. Of the remaining 455, 85% agreed to receive the invitation
letter. The higher uptake rates of ICs in this study in the clinic
phase than in the postal phase is similar to that found in a US
study contacting prostate cancer patients to collect data on family
history of cancer (Plaetke et al, 2002). Reasons for non-
participation of ICs included not having told their relatives that
they had cancer, similar to our study.
In the clinic phase, the overall uptake rate of FDRs proceeding to
a PSA test among those ICs with eligible relatives willing to receive
the invitation letter was 41% (158 out of 389). The greatest loss
occurred at the stage when ICs were asked to provide signed
consent for their relative to be contacted (49%; 192 out of 389
consented). As ICs were encouraged to discuss the study with their
relative, both men will have contributed to the non-response. Of
those FDRs receiving an invitation letter, 87% (167 out of 192)
consented to provide a PSA measurement, either present or
previous, and 95% of the 167 proceeded to do so. First-degree male
relatives were more likely to consent and proceed with screening
if they were married/co-habiting than living with no partner
(Po0.05): among FDRs who initially consented, 94% (190 out of
202) providing a PSA test were living with a partner compared with
78% (14 out of 18) who did not proceed. Data on socio-economic
status were not collected. The higher detection of prostate cancer
in non-manual than manual social class groups is partly
considered to reflect difference in use of health service (Neal and
Allgar, 2005), and similar trends are likely to be seen in relatives.
No Africans or African-Caribbeans participated in our study,
although part of the London area would have included patients
from this ethnic group. Some may have chosen not to take part and
others may only have had relatives living abroad. These men
remain an important group to study in the UK. In the UK, a higher
prostate cancer mortality rate was found in West African and
Caribbean migrants than in men born in England and Wales
(Grulich et al, 1992). Research in the US shows that the risk of
prostate cancer is higher in African Americans than in white
Americans (Hsing et al, 2000), but the natural history is not
understood fully (Freedland et al, 2000).
Other studies have shown that FDRs are less likely to be
screened if they have high levels of anxiety (Bratt et al, 2000;
Roumier et al, 2004) and had more than one affected FDR
(Roumier et al, 2004). Psychosocial factors are explored further in
the accompanying paper (refer Sweetman et al, 2006). Counselling
of FDRs in our study was restricted because of the ethical
requirement that they could not be contacted directly until the IC
and FDR had given signed consent.
Limitations with our study include the fact that, in the clinic
phase, the ascertainment rate of all potentially eligible ICs could
not be estimated in all hospitals. There was a lack of routine
standardised data sources in the hospitals to identify patients and
their dates of appointments. As the NCRN staff often worked
mainly in oncology, patients managed in urology could have been
missed in some hospitals unless a urology or uro-oncology nurse
specialist was involved. Also, patients on active surveillance who
were being monitored by their GP and did not attend during the
period of data collection would have been missed. The most
complete ascertainment is likely to have occurred at RMH and
Salisbury where a combination of clinic and postal methods was
Table 3 Results of PSA screening by the FDRs’ reporting of history of previous PSA testing
PPV of referral
a PPV of biopsy
b
Source of PSA test
No. of men
screened
No. of men
referred (%)
No. of men
biopsied (%)
No. of men with
cancer (%) % (95% CI) % (95% CI)
Central+local lab, no prior
PSA tests or not known
122 13 (10.7) 12 (9.8) 4 (3.3) 30.8 (9, 61) 33.3 (10, 65)
Central+local lab with prior
PSA tests
48 8 (16.7) 4 (8.3) 1 (2.1) 12.5 (0, 53) 25.0 (1, 81)
Total 170 21 (12.4) 16 (9.4) 5 (2.9) 23.8 (8, 47) 31.2 (11, 59)
aThe proportion of men diagnosed with prostate cancer on biopsy out of all men with a raised PSA who were recommended by the study protocol to be referred.
bThe
proportion of men diagnosed with prostate cancer on biopsy out of all men with a raised PSA who were recommended by the study protocol to be referred, and who actually
proceeded to have a biopsy taken. PSA¼prostate-specific antigen; FDR¼first-degree male relative; PPV¼positive predictive value.
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sused to ensure that all potential eligible ICs on the hospital
database were contacted.
The level of prostate cancer awareness and the rate of PSA
testing already taking place in the UK will also have affected uptake
in this study. Although ICs and FDRs were encouraged to
participate even if the FDR had already been tested, it is uncertain
what proportion of non-responders was eligible but had been
previously screened. Previous testing was a reason for non-
participation in a study of families with a high risk of prostate
cancer in France (Roumier et al, 2004). In our study, 31% of FDRs
reported having had a previous PSA test. In the accompanying
psychosocial paper (refer Sweetman et al, 2006), it is reported that
out of the 60% of FDRs who took part in the study, 41% (52 out of
128) had a blood test screening for prostate cancer. The true rate of
prior screening cannot be accurately estimated from self-reported
data, but the rate of prior testing in the study participants is
certainly higher than that reported in the general UK population
(Melia et al, 2004).
The study identified practical difficulties associated with
identification of eligible patients and with arrangements for
screening and referral. Without routine recording of family history
of cancer, it is very difficult to identify eligible families. There was
also a high workload associated with arranging the screening test
and referral, as most GPs were only screening one patient and each
GP practice needed support to follow the study protocol.
The percentage of PSA levels X4ngml
 1 in our study (10%) is
similar to that reported in high-risk men in the Finnish arm of the
European trial (Makinen et al, 2002) (11%). This percentage is
higher than that in the general population: in the European general
population screening trial in men with no family history (Makinen
et al, 2002) screened in Finland and in men screened in Sweden
(Hugosson et al, 2003), the percentages were 7.7 and 6.7%
respectively in the prevalence round. In the study of high-risk
families in France (Roumier et al, 2004), 5.7% of relatives had PSA
levels 44ngml
 1, but most of the relatives were sons below the
age of 50 years. In the study of FDRs in families with X2 brothers
with prostate cancer in the USA (McWhorter et al, 1992), the
proportion was 18%, but the FDRs belonged to families with a
higher level of risk than in our study. In our study, the proportion
was 16% (five out of 32) in FDRs providing a previous
measurement, but the result may have been biased if the men
who were worried by a previous test result were more likely to
participate than those with lower readings.
The overall PPV of referral in our study (24%) was slightly lower
than that reported in the Finnish study screening men with a
family history of prostate cancer (Makinen et al, 2002) (27.6%) and
was not significantly different from that in the general population
(20%) (Roobol and Schroder, 2003). Although higher PPVs have
been reported (33% (Matikainen et al, 1999) and 32% (Roumier
et al, 2004)), these were in studies of relatives from families with
X2 relatives with prostate cancer, compared with X1 in our
study. The PPV in our study could have been affected by variation
in the biopsy protocol between hospitals. Despite a standardised
protocol, recommending eight biopsy cores to be taken,
being sent to each FDR’s consultant, in most cases the local
protocol was used with a range of 6–12 cores. As the histological
diagnosis of all men biopsied was checked and confirmed by the
study review pathologist, observer variation in diagnosis and
grading between pathologists is not expected to have affected
the results.
Our study was not designed to have the power to study detection
rates of prostate cancer. The level of risk from prostate cancer is
expected to be lower than in families with X2 FDRs with prostate
cancer. Furthermore, families where the FDR had already been
diagnosed with prostate cancer were excluded, and families of ICs
who had died were not approached, so some families with perhaps
a more aggressive form of the disease may have been excluded. It is
not known what the uptake rate of screening would be in FDRs of
ICs who had died from cancer.
Increased PSA testing in the general population has led to more
men under the age of 60 years being tested both in the general
population (Marotte et al, 2004; Hemminki et al, 2005) and in
families with a history of the disease (Bock et al, 2005). Testing will
bring forward the date of diagnosis and it will increase the
diagnosis of slow-growing cancers, some of which may not be life
threatening. Reports on the natural history of prostate cancer in
high-risk men should consider the extent to which background
PSA testing in the population and the selection criteria for families
being studied may have influenced the results.
The effects of screening on prostate cancer mortality and quality
of life in the general population and in high-risk groups remain
uncertain. Most organisations, including the NHS Prostate Cancer
Risk Management Programme, advise an informed choice
approach if men request screening, so that they can weigh up
the advantages and disadvantages (Hewitson and Austoker, 2005).
The best evidence on the outcome of screening is likely to come
from the randomised controlled trials. However, these were not
designed and will not have the power to study adequately the
effects of screening in high-risk groups. For the present, the impact
of screening on these groups may have to be modelled using data
from the general population.
In conclusion, these results have implications for the way that
targeted prostate cancer PSA screening may be offered to high-risk
groups. For example, there is a new study, IMPACT (The
Identification of Men with genetic predisposition to ProstAte
Cancer: Targeted screening in BRCA1/2 mutation carriers), and
our study has informed the way that these men are invited into the
study. While the results of the screening trials are awaited, PSA
testing is likely to continue, and provision should be made for the
counselling and provision of information to patients diagnosed at
a young age to help them understand familial risk. Research is
needed into the management of men with a very high risk of the
disease, for example carriers of the BRCA2 gene (Edwards et al,
2003). Cancer networks could have a key role in ensuring that
these men and their relatives are offered counselling. The study
results emphasise the need for standardised data to be recorded
nationally on the outcome of screening so that the effects of
screening can be studied.
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